1. What Is the Targeted Sequencing Market?
The Targeted Sequencing Market covers gene panel hybrid capture kits, amplicon panel sequencing assays, FDA-cleared companion diagnostic NGS panels, and clinical targeted sequencing bioinformatics pipelines. These systems selectively sequence specific genes, exons, or genomic regions relevant to clinical questions. Applications include oncology somatic variant companion diagnostics, hereditary cancer risk panel testing, inherited cardiomyopathy gene panels, and liquid biopsy circulating tumor DNA panels. Market dynamics reflect FDA companion diagnostic NGS panel approvals and somatic cancer panel reimbursement growth. Hereditary cancer multi-gene panel adoption and liquid biopsy ctDNA panel validation further support expansion. Targeted sequencing balances analytical sensitivity with cost efficiency for high-volume clinical testing.
2. Targeted Sequencing Market Size & Forecast
3. Emerging Technologies
- Ultra-sensitive targeted panels with unique molecular identifiers achieving 0.01% variant allele frequency are advancing. Growing clinical adoption is driven by MRD detection and early relapse monitoring requirements.
- Pan-cancer somatic panels covering 500-plus genes for tumor mutational burden and MSI are advancing. Growing pharmaceutical adoption is driven by checkpoint inhibitor biomarker standardization across clinical trials.
- Methylation-based targeted sequencing panels for epigenetic cancer tissue-of-origin determination are advancing. Growing use is driven by CUP and metastatic disease tissue-of-origin clinical diagnostic applications.
- Targeted RNA fusion and splice variant panels for actionable fusion gene detection are advancing. Growing clinical adoption is driven by ALK, RET, NTRK, and ROS1 fusion companion diagnostic requirements.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Whole Exome Sequencing Market.
4. Key Market Opportunity
The primary opportunity in the Targeted Sequencing Market is FDA companion diagnostic panel adoption. ctDNA liquid biopsy targeted sequencing creates a high-value oncology monitoring market segment. Hereditary cancer multi-gene panel testing creates population screening market opportunity. Asia Pacific targeted sequencing market growth in China and Japan creates geographic opportunity.
5. Top Companies in the Targeted Sequencing Market
The following organisations hold leading positions in the Targeted Sequencing Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Foundation Medicine (Roche, F1CDx)
- Illumina (TSO500)
- Thermo Fisher (Oncomine)
- Guardant Health (Guardant360 CDx)
- Tempus (xT panel)
- Caris Life Sciences
- InVitae (hereditary panels)
- Myriad Genetics (myRisk)
- Ambry Genetics
- IDT (xGen panel design)
6. Market Segmentation
The Targeted Sequencing Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Type | Solid Tumor Somatic Panels Hereditary Cancer Panels ctDNA Liquid Biopsy Panels Cardiomyopathy Panels |
| By Chemistry | Hybrid Capture Amplicon PCR Unique Molecular Identifiers |
| By End User | Hospital Molecular Pathology Labs Commercial Diagnostic Labs Pharmaceutical CROs |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Targeted Sequencing Market trajectory over the forecast period:
FDA Companion Diagnostic NGS Panels Are Linking Targeted Therapy Prescribing to Genomic Testing.FDA-approved companion diagnostic gene panels identify patients eligible for targeted cancer therapies. Foundation Medicine F1CDx and Illumina TSO500 are the leading FDA-cleared cancer companion diagnostic panels. Each CDx approval creates mandatory NGS testing requirements that drive panel adoption at oncology centers. Growing targeted therapy approvals with NGS CDx requirements are directly expanding targeted sequencing volume.
Liquid Biopsy ctDNA Targeted Panels Are Advancing Treatment Monitoring Without Tumor Rebiopsy.Cell-free DNA targeted panels detect somatic mutations in circulating tumor DNA from blood samples. These panels monitor treatment response, detect acquired resistance mutations, and track minimal residual disease. Guardant360 CDx and Foundation Medicine FoundationOne Liquid CDx are FDA-cleared ctDNA companion diagnostics. Liquid biopsy targeted sequencing is reducing the need for invasive tissue rebiopsy in oncology management.
Hereditary Cancer Multi-Gene Panel Testing Is Advancing Population-Level Cancer Risk Identification.Multi-gene panels testing BRCA1, BRCA2, ATM, CHEK2, PALB2, and 40-100 additional cancer risk genes. These panels identify hereditary risk beyond BRCA2 in patients without obvious BRCA indications. Population-based hereditary cancer screening programs are broadening hereditary panel testing beyond high-risk referrals. Expanded panel testing is identifying additional risk gene variants that inform preventive surveillance strategies.
For related market intelligence, see the Whole Genome Sequencing Market.
8. Segmental Analysis
By type, the Solid Tumor Somatic Companion Diagnostic Panel segment dominated the Targeted Sequencing Market in 2025. FDA CDx approvals and reimbursement create mandatory testing demand at oncology institutions. The ctDNA Liquid Biopsy Panel segment is fastest-growing, driven by treatment monitoring and MRD detection adoption.
9. Regional Analysis
Regional demand patterns across the Targeted Sequencing Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Targeted Sequencing Market in 2025 with a market share of 43.0%. The region hosts Foundation Medicine, Guardant Health, Tempus, and Caris and the leading panel sequencing companies. FDA companion diagnostic approvals create non-discretionary NGS panel testing demand at US oncology centers. Moreover, US commercial insurance coverage of hereditary cancer multi-gene panels drives testing volume. In addition, North America leads ctDNA liquid biopsy companion diagnostic clinical trial and approval programs. CDx leadership and commercial coverage sustain North American dominance through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR of 18.06% in the Targeted Sequencing Market through 2034. China's growing oncology targeted sequencing market is driven by companion diagnostic adoption at cancer hospitals. Japan's established clinical oncology NGS panel market and hereditary testing programs create institutional demand. Moreover, South Korea's precision oncology program and national cancer genetic testing coverage create market growth. Oncology adoption and precision medicine programs position Asia Pacific for sustained Targeted Sequencing Market outperformance.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Targeted Sequencing Market was valued at USD 2.60 Bn in 2025 and is projected to reach USD 7.75 Bn by 2034, growing at a CAGR of 12.90% over the 2026–2034 forecast period.
The Targeted Sequencing Market is projected to grow at a CAGR of 12.90% from 2026 to 2034.
North America dominated the Targeted Sequencing Market in 2025 with a market share of 43.0%.
The leading companies in the Targeted Sequencing Market include Foundation Medicine (Roche, F1CDx), Illumina (TSO500), Thermo Fisher (Oncomine), Guardant Health (Guardant360 CDx), Tempus (xT panel), Caris Life Sciences, InVitae (hereditary panels), Myriad Genetics (myRisk), Ambry Genetics, IDT (xGen panel design).
Fda companion diagnostic ngs panels are linking targeted therapy prescribing to genomic testing.
By type, the Solid Tumor Somatic Companion Diagnostic Panel segment dominated the Targeted Sequencing Market in 2025.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 3 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 3 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 3 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.